Literature DB >> 11007829

Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy.

C W Yoo1, M K Kim, H S Lee.   

Abstract

BACKGROUND: Diffuse proliferative lupus nephropathy (DPLN) is the most frequent and severe form of renal disease in patients with systemic lupus erythaematosus. Histological parameters at the initial biopsy of patients with DPLN that would predict the progression of renal pathology or function at the second biopsy are not clearly defined.
METHODS: The prognostic significance of renal histological indices, such as glomerular activity index and volume density of cortical interstitium [Vv(int/cortex)], was evaluated from successive renal biopsies in 21 patients with DPLN.
RESULTS: At the time of the second biopsies, performed an average of 43 months after the first biopsies, seven patients (33%) showed progressive renal insufficiency. Only three cases (14%) transformed to World Health Organization class I or III. The seven patients with clinical progression exhibited a higher frequency of hypertension, higher percent glomerulosclerosis, and larger Vv(int/cortex) at the time of second biopsy as compared with the 14 patients without renal insufficiency. At the first biopsy, patients with clinical progression showed a higher glomerular activity index (2.9+/-1.2 vs 1.3+/-0.8, P<0.05) and larger Vv(int/cortex) (0.13+/-0.07 microm(3)/microm(3) vs 0.05+/-0.03 microm(3)/microm(3), P<0.05) than the patients without progression. The glomerular activity index at the first biopsy correlated directly with per cent glomerulosclerosis, Vv(int/cortex), and serum creatinine level at the second biopsy. Vv(int/cortex) in the first biopsy also showed a significant relation with per cent glomerulosclerosis and serum creatinine level at the second biopsy.
CONCLUSIONS: These results suggest that higher glomerular activity and larger interstitial volume density at the initial biopsy can predict future progression of renal pathology or function in DPLN.

Entities:  

Mesh:

Year:  2000        PMID: 11007829     DOI: 10.1093/ndt/15.10.1604

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  12 in total

1.  Characteristics and influence factors of pathologic transformation in the subclasses of class IV lupus nephritis.

Authors:  Jian-jun Gao; Guang-yan Cai; Shu-wen Liu; Li Tang; Xue-guang Zhang; Yang Yang; Pu Chen; Shu-xin Liu; Jia-yao Ji; Suo-zhu Shi; Zhong Yin; Xiang-mei Chen
Journal:  Rheumatol Int       Date:  2011-03-26       Impact factor: 2.631

2.  Clinical outcomes of childhood lupus nephritis: a single center's experience.

Authors:  Byong Sop Lee; Hee Yeon Cho; Eo Jin Kim; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong; Joong Gon Kim; Hyun Soon Lee; Yong Choi
Journal:  Pediatr Nephrol       Date:  2006-11-28       Impact factor: 3.714

3.  A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies.

Authors:  Xiaolan Zhang; Haikady N Nagaraja; Tibor Nadasdy; Huijuan Song; Alison McKinley; Jason Prosek; Swapna Kamadana; Brad H Rovin
Journal:  Kidney Int       Date:  2011-10-12       Impact factor: 10.612

4.  Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?

Authors:  Eid M El-Shafey; Said H Abdou; Mohamed M Shareef
Journal:  Clin Exp Nephrol       Date:  2010-02-19       Impact factor: 2.801

Review 5.  A Histology-Guided Approach to the Management of Patients with Lupus Nephritis: Are We There Yet?

Authors:  Bogdan Obrișcă; Alexandra Vornicu; Alexandru Procop; Vlad Herlea; George Terinte-Balcan; Mihaela Gherghiceanu; Gener Ismail
Journal:  Biomedicines       Date:  2022-06-15

6.  Male gender results in more severe lupus nephritis.

Authors:  Jozélio Freire de Carvalho; Ana Patrícia do Nascimento; Leonardo A Testagrossa; Rui Toledo Barros; Eloísa Bonfá
Journal:  Rheumatol Int       Date:  2009-09-27       Impact factor: 2.631

7.  Efficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis.

Authors:  Jian Sun; Hao Zhang; Ying Ji; Ming Gui; Bin Yi; Jianwen Wang; Juan Jiang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis.

Authors:  Carolina Landolt-Marticorena; Stephenie D Prokopec; Stacey Morrison; Babak Noamani; Dennisse Bonilla; Heather Reich; James Scholey; Carmen Avila-Casado; Paul R Fortin; Paul C Boutros; Joan Wither
Journal:  Arthritis Res Ther       Date:  2016-10-04       Impact factor: 5.156

Review 9.  The value of repeat biopsy in lupus nephritis flares.

Authors:  Javier Narváez; Milagros Ricse; Montserrat Gomà; Francesca Mitjavila; Xavier Fulladosa; Olga Capdevila; Joan Torras; Xavier Juanola; Ramón Pujol-Farriols; Joan Miquel Nolla
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

10.  Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort.

Authors:  Kunihiro Ichinose; Mineaki Kitamura; Shuntaro Sato; Keita Fujikawa; Yoshiro Horai; Naoki Matsuoka; Masahiko Tsuboi; Fumiaki Nonaka; Toshimasa Shimizu; Remi Sumiyoshi; Tomohiro Koga; Shin-Ya Kawashiri; Naoki Iwamoto; Takashi Igawa; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Tomoya Nishino; Atsushi Kawakami
Journal:  Arthritis Res Ther       Date:  2020-07-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.